Engineering cell-based ovarian hormone therapy

Abstract

Biomimetic endocrine implants bridge tissue engineering and reproductive medicine to offer adaptive and long-lasting hormone therapies for the treatment of ovarian premature insufficiency and menopause. Their clinical translation requires aligned regulatory, ethical and manufacturing pathways.